734 
2591国家医保谈判作为促进医疗、医保、医药“三医”协同的制度创新，为新时代深化医药卫生体制改革、增进人民健康福祉提供了有效方案。文章基于2016—2020年抗癌类医保谈判药品的全国销售数据以及2010—2018年各类癌症的死亡率数据，运用多时点双重差分法，评估了国家医保谈判的经济效应与健康效应。研究发现，对于医药厂商而言，医保谈判政策实施使相关抗癌药品的销售量和销售收入均显著上升，其对销售利润的影响则取决于药品的成本水平。对于患者而言，该政策实施后对应癌症类型的死亡人数显著下降。异质性分析表明，该政策效果在有更多对症谈判药品的癌症类型样本中更为显著，并且在较为罕见的癌症类型中，城市地区的政策效果更加显著。进一步的成本收益分析发现，医保谈判在合理的成本范围内拯救了众多患者的生命，具有较好的经济收益。文章综合评估了国家医保谈判在抗癌领域产生的社会经济价值，并为进一步提升医保基金使用效能提供了有益参考。
和衷共济，利在其中：国家医保谈判的经济效应与健康效应
摘要
参考文献
9 余典范, 王超, 李鑫. 何种政府采购能发挥靶向创新效应?——来自上市公司的证据[J]. 会计研究, 2023, (10): 88−100. DOI:10.3969/j.issn.1003-2886.2023.10.007
10 张庆霖, 郭嘉仪. 政府规制、买方势力与技术创新: 中国制药产业的研究[J]. 当代财经, 2013, (6): 98−109.
11 张新鑫, 侯文华, 申成霖. 价格管制、战略性创新激励与创新药市场绩效[J]. 科研管理, 2017, (10): 68−75.
12 Armstrong M, Vickers J. Welfare effects of price discrimination by a regulated monopolist[J]. The RAND Journal of Economics, 1991, 22(4): 571−580. DOI:10.2307/2600990
13 Bajari P, McMillan R, Tadelis S. Auctions versus negotiations in procurement: An empirical analysis[J]. The Journal of Law, Economics, and Organization, 2009, 25(2): 372−399. DOI:10.1093/jleo/ewn002
14 Blume-Kohout M E, Sood N. Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development[J]. Journal of Public Economics, 2013, 97: 327−336. DOI:10.1016/j.jpubeco.2012.10.003
15 Caves R E, Whinston M D, Hurwitz M A. Patent expiration, entry, and competition in the U.S. pharmaceutical industry[J]. Brookings Papers on Economic Activity. Microeconomics, 1991: 1−66. DOI:10.2307/2534790
16 DiMasi J A, Grabowski H G, Hansen R W. Innovation in the pharmaceutical industry: New estimates of R&D costs[J]. Journal of Health Economics, 2016, 47: 20−33. DOI:10.1016/j.jhealeco.2016.01.012
17 DiStefano M J, Levy J F, Odouard I C, et al. Estimated savings from using added therapeutic benefit and therapeutic reference pricing in United States Medicare drug price negotiations[J]. Value in Health, 2023, 26(11): 1618−1624. DOI:10.1016/j.jval.2023.08.004
18 Duggan M, Morton F S. The effect of Medicare Part D on pharmaceutical prices and utilization[J]. The American Economic Review, 2010, 100(1): 590−607. DOI:10.1257/aer.100.1.590
19 Gretschko V, Wambach A. Procurement under public scrutiny: Auctions versus negotiations[J]. The RAND Journal of Economics, 2016, 47(4): 914−934. DOI:10.1111/1756-2171.12159
20 Inderst R, Wey C. Buyer power and supplier incentives[J]. European Economic Review, 2007, 51(3): 647−667. DOI:10.1016/j.euroecorev.2006.02.002
21 Lakdawalla D, Sood N. Innovation and the welfare effects of public drug insurance[J]. Journal of Public Economics, 2009, 93(3-4): 541−548. DOI:10.1016/j.jpubeco.2008.11.003
22 Leininger W. Patent competition, rent dissipation, and the persistence of monopoly: The role of research budgets[J]. Journal of Economic Theory, 1991, 53(1): 146−172. DOI:10.1016/0022-0531(91)90146-U
23 Linnosmaa I, Hermans R, Hallinen T. Price-cost margin in the pharmaceutical industry: Empirical evidence from Finland[J]. The European Journal of Health Economics, 2004, 5(2): 122−128.
24 Moye-Holz D, Van Dijk J P, Reijneveld S A, et al. The impact of price negotiations on public procurement prices and access to 8 innovative cancer medicines in a middle-income country: The case of Mexico[J]. Value in Health Regional Issues, 2019, 20: 129−135. DOI:10.1016/j.vhri.2019.04.006
25 Vernon J A. Examining the link between price regulation and pharmaceutical R&D investment[J]. Health Economics, 2005, 14(1): 1−16. DOI:10.1002/hec.897
26 Yin X J, Xu Y, Man X W, et al. Direct costs of both inpatient and outpatient care for all type cancers: The evidence from Beijing, China[J]. Cancer Medicine, 2019, 8(6): 3250−3260. DOI:10.1002/cam4.2184
27 Zhang X, Nie H H. Public health insurance and pharmaceutical innovation: Evidence from China[J]. Journal of Deve- lopment Economics, 2021, 148: 102578. DOI:10.1016/j.jdeveco.2020.102578
引用本文
毛晖, 张泽丰, 陈政弘. 和衷共济，利在其中：国家医保谈判的经济效应与健康效应[J]. 财经研究, 2025, 51(9): 64-78.
导出参考文献，格式为：
